CMC Services & Analytical Sciences Capabilities
Our multidisciplinary approach combines expert product and process knowledge with a quality-first mindset to ensure Right First Time submissions across the globe.
Meet our CMC Services & Analytical Sciences Experts
Ryan Doxey
SENIOR DIRECTOR, TECHNICAL SERVICES



Helpful Links
Here are some of our favorite resources on this topic
Markets That Benefit from Our CMC Services & Analytical Sciences Solutions
Combination Products
Our experts understand the interaction between devices and drug products. Our experience includes injectables, nasal, respiratory, and more.
Biologics & Cell and Gene Therapy Services
We understand why “the product is the process” and how to implement solutions to your unique challenges.




The Kymanox CMC Services & Analytical Sciences Difference
At Kymanox we are more than consultants. We are partners with our clients and create custom solutions that meet each client’s unique needs. If you're looking for the CMC services businesses rely on, get in touch with us today.

Flexibility & Agility
At Kymanox, we make it easy for clients to get the solutions they need, when they need it. Clients tell us our flexibility is one of the key reasons they keep coming back.

Proven Broad Expertise
Our team of experts is focused on life sciences with extensive experience across drug and device development. No matter your challenge, we can help you conquer it.

Dynamic Project Management
A personalized approach to project management that combines your needs with our proven tools and expertise to create a custom solution for your project.
Frequently Asked CMC Services & Analytical Sciences Questions (FAQs)
Can Kymanox author CMC (Quality) Sections of my IND, NDA, ANDA, or BLA?
Kymanox has an expert staff of regulatory and technical writers who are intimately familiar with authoring the CMC (Quality) sections for all submission types. Kymanox is also well versed in preparing all sections of your submission, as well as Briefing Packages to support communications from Pre-IND through Pre-NDA/BLA.
What other documents can Kymanox author?
The comprehensive CMC support offered by Kymanox includes, but is not limited to, Quality by Design (QbD) documentation including CQAs and CPPs, Target Product Profile (TPP), and Quality TPP (QTPP), as well as Common Technical Document (CTD) Module 3 (i.e., 3.2S and 3.2P) authoring for submission of global investigational products and market authorization.
Can Kymanox handle regulatory submissions outside the US?
Yes, the Kymanox team is experienced with the regional regulatory requirements and expectations for submissions to EU, Japan, Brazil, and Canada.
Can Kymanox help with my pharmaceutical/combination product development and regulatory strategy?
Yes, Kymanox’s expert staff of pharmaceutical development scientists and drug delivery device engineers can provide a breadth of strategic development and regulatory planning services throughout the stages of clinical development and up to market authorization. Kymanox is well versed in navigating the complexities of product development to deliver and maximize the potential for commercial success. These services include, but are not limited to, the evaluation of formulation technologies and selection and optimization of drug product formulation; evaluation of manufacturing process technologies, process development, scale-up, and technology transfer; analytical and microbiological method development and validation support; technical writing of protocols and reports; evaluation, selection, and optimization primary packaging components and drug delivery systems; stability study strategy and design; and the evaluation and selection of contract organizations.
Can Kymanox help with the selection and setup of my laboratory instrumentation and equipment?
Absolutely! The Kymanox Analytical Sciences group has professionals with global experience working with a vast array of laboratory instrumentation and equipment from bench-scale to commercial-scale in the pharmaceutical, biotechnology, medical device, and in vitro diagnostic industries. We provide on-going support for all phases of development, from discovery to post-commercialization, with services ranging from research and selection of instrumentation/equipment that are best suited to your project needs, setup and qualification of instrumentation/equipment intended for GxP use, as well as troubleshooting issues with system performance and/or assay optimization.
Read the Latest at Kymanox
Kymanox Acquires EU Based Anteris Medical and Anteris Helvetia
Leveraging the well-respected anteris brand and team, this acquisition extends Kymanox’s capabilities and geographic reach with a strong European presence
Friday, 03 February 2023
Morrisville, North Carolina, USA and Holzkirchen, Germany an...
Interview: Kymanox Executive Advisors Mathias Romacker, Fran DeGrazio & Paul Jansen
Kymanox Executive Advisors (KEAs) Mathias Romacker, Fran DeGrazio, and Paul Jansen sit down with Guy Furness to discuss what has driven Kymanox's rapid rise in the drug delivery space and what makes the consulting company's model so successful, as well...
Growing Happy Cells: Bioreactor Optimization
Biologics, including cell and gene therapies, have become a hot topic in the pharmaceutical industry as their therapeutic applications expand. Challenges of developing biologic drug products include scale-up for commercial manufacturing and production ...